To Describe the Effect of rhLH Supplementation in Women With Hyporesponse to rhFSH After Pituitary Downregulation
A Multicentre, Prospective, Open Study to Describe the Effects of rhLH Supplement in Women With Hyporesponse to rFSH After Pituitary Downregulation.
Sponsor: Chongqing Medical Center for Women and Children
Listed as NCT01029470, this PHASE2 trial focuses on Infertility and remains ongoing. Sponsored by Chongqing Medical Center for Women and Children, it has been updated 7 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Feb 2023 — Jul 2024 [monthly]
Unknown Status PHASE2
-
Jan 2021 — Feb 2023 [monthly]
Unknown Status PHASE2
-
Aug 2018 — Jan 2021 [monthly]
Unknown Status PHASE2
▶ Show 2 earlier versions
-
Jul 2018 — Aug 2018 [monthly]
Unknown Status PHASE2
-
Jan 2017 — Jul 2018 [monthly]
Unknown Status PHASE2
First recorded
Dec 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Chongqing Medical Center for Women and Children
- Peking Union Medical College Hospital
- Peking University Third Hospital
- Reproductive & Genetic Hospital of CITIC-Xiangya
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
For direct contact, visit the study record on ClinicalTrials.gov .